2026 Global: Companion Diagnostics Market-Competitive Review (2032) report
Description
The 2026 Global: Companion Diagnostics Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for companion diagnostics market by geography and historical trend. The scope of the report extends to sizing of the companion diagnostics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Roche (F. Hoffmann-La Roche Ltd), Agilent Technologies, QIAGEN, Thermo Fisher Scientific, and Abbott Laboratories lead the companion diagnostics market, followed by bioMérieux, Illumina, Myriad Genetics, Foundation Medicine, and Guardant Health as the ten major companies. These firms dominate through extensive portfolios in PCR, NGS, and IHC assays, capturing significant shares amid a market projected to grow from USD 8.7-9.7 billion in 2025 to USD 15.6-16.0 billion by 2030 at CAGRs of 10.5-12.4%. Roche holds the top position with its cobas platform and Ventana IHC systems, integrated via Genentech for oncology therapies like PD-L1 and HER2 biomarkers, bolstered by partnerships such as with PathAI for digital pathology. Agilent ranks second, excelling in NGS panels and FDA-approved PD-L1 IHC 22C3 for gastric cancers, leveraging R&D investments and global distribution. QIAGEN follows with therascreen PCR kits for KRAS mutations, expanding CDx claims through robust North American, European, and Asian networks.
Thermo Fisher Scientific and Abbott provide comprehensive platforms, while Illumina drives NGS innovation. Thermo Fisher offers end-to-end solutions including Oncomine NGS assays for lung and breast cancers, partnering with pharma for precision oncology and supporting software upgrades amid regulatory shifts. Abbott advances with Alinity systems for biomarker detection in infectious diseases and oncology, maintaining U.S. leadership via strong R&D allocation. Illumina pioneers portable NGS kits, collaborating on panels that outpace PCR at 14.3% CAGR, emphasizing sequencing efficiency for personalized medicine. bioMérieux contributes PCR-based tests for antimicrobial resistance, holding steady European presence.
Myriad Genetics, Foundation Medicine, and Guardant Health focus on oncology genomics, fueling market expansion. Myriad's myRisk panels identify hereditary cancers, integrating with pharma for BRCA testing. Foundation Medicine's FoundationOne CDx, acquired by Roche, analyzes 300+ genes for tumor profiling, accelerating approvals. Guardant Health's liquid biopsies like Guardant360 detect ctDNA for minimal residual disease, partnering regionally for NGS expansion. These ten companies drive 66.3% assay dominance and software growth at 15.8% CAGR, propelled by precision medicine, cancer prevalence, and FDA endorsements. Their strategies—R&D, acquisitions, collaborations—navigate NGS disruption and regulatory evolution.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for companion diagnostics market by geography and historical trend. The scope of the report extends to sizing of the companion diagnostics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Roche (F. Hoffmann-La Roche Ltd), Agilent Technologies, QIAGEN, Thermo Fisher Scientific, and Abbott Laboratories lead the companion diagnostics market, followed by bioMérieux, Illumina, Myriad Genetics, Foundation Medicine, and Guardant Health as the ten major companies. These firms dominate through extensive portfolios in PCR, NGS, and IHC assays, capturing significant shares amid a market projected to grow from USD 8.7-9.7 billion in 2025 to USD 15.6-16.0 billion by 2030 at CAGRs of 10.5-12.4%. Roche holds the top position with its cobas platform and Ventana IHC systems, integrated via Genentech for oncology therapies like PD-L1 and HER2 biomarkers, bolstered by partnerships such as with PathAI for digital pathology. Agilent ranks second, excelling in NGS panels and FDA-approved PD-L1 IHC 22C3 for gastric cancers, leveraging R&D investments and global distribution. QIAGEN follows with therascreen PCR kits for KRAS mutations, expanding CDx claims through robust North American, European, and Asian networks.
Thermo Fisher Scientific and Abbott provide comprehensive platforms, while Illumina drives NGS innovation. Thermo Fisher offers end-to-end solutions including Oncomine NGS assays for lung and breast cancers, partnering with pharma for precision oncology and supporting software upgrades amid regulatory shifts. Abbott advances with Alinity systems for biomarker detection in infectious diseases and oncology, maintaining U.S. leadership via strong R&D allocation. Illumina pioneers portable NGS kits, collaborating on panels that outpace PCR at 14.3% CAGR, emphasizing sequencing efficiency for personalized medicine. bioMérieux contributes PCR-based tests for antimicrobial resistance, holding steady European presence.
Myriad Genetics, Foundation Medicine, and Guardant Health focus on oncology genomics, fueling market expansion. Myriad's myRisk panels identify hereditary cancers, integrating with pharma for BRCA testing. Foundation Medicine's FoundationOne CDx, acquired by Roche, analyzes 300+ genes for tumor profiling, accelerating approvals. Guardant Health's liquid biopsies like Guardant360 detect ctDNA for minimal residual disease, partnering regionally for NGS expansion. These ten companies drive 66.3% assay dominance and software growth at 15.8% CAGR, propelled by precision medicine, cancer prevalence, and FDA endorsements. Their strategies—R&D, acquisitions, collaborations—navigate NGS disruption and regulatory evolution.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
